Third Strike For Peregrine's Bavituximab
This article was originally published in Scrip
Executive Summary
You may also be interested in...
Peregrine Officially End Late-Stage Development of Bavituximab
The biotech continues to look for alternative data that could resurrect its lead product after a slew of failures.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.